ABSTRACT. Nuclear factor-kB (NF-kB), a transcription factor that is activated by various stimuli, is associated with the pathogenesis of several cancers. One functional polymorphism, -94 insertion/deletion ATTG (rs28362491), in the human NFKB1 gene (one member of the NF-kB gene family) is associated with increased risk of various cancers. However, only one study has reported that rs28362491 is significantly associated with ovarian cancer. The aim of this study was to analyze the association between single nucleotide polymorphisms (SNPs) and haplotypes in the NFKB1 gene and the risk of ovarian cancer in a Chinese population. We examined the potential association between ovarian cancer and
INTRODUCTION
Ovarian cancer is the leading cause of death among all gynecological cancers. Its early symptoms are often not apparent, and its early diagnosis is therefore difficult, resulting in a low 5-year survival rate of approximately 30% (Jemal et al., 2010) . As a polygenic disease, the pathogen esis of ovarian cancer is multifactorial, which means that multiple genetic factors may be associated with its development and progression (Gulden and Olopade, 2010) . Previous studies have suggested that polymorphisms in nuclear factor-kB (NF-kB), a transcription factor that is activated by various stimuli, may be associated with ovarian cancer (Yang et al., 2014) .
NF-kB is a major transcription regulator of immune response, apoptosis, and cellgrowth control genes, and is involved in the pathogenesis of several cancers (Naugler and Karin, 2008; Karin, 2009) , including epithelial ovarian cancer (EOC) (Hernandez et al., 2010) . There are five members of the NF-kB family in mammals: p50/p105, p65/RelA, c-Rel, RelB, and p52/p100. The major form of NF-kB is a heterodimer of the p50 subunit, which is encoded by the NFKB1 gene (Chen et al., 1999) . The p50 subunit inhibits cell apoptosis by regulating several survival genes, such as bcl-2 homologue A1 (Karsan et al., 1996) , PAI-2 (Kumar and Baglioni, 1991) , and the IAP gene family (LaCasse et al., 1998) . Certain anti-apoptosis proteins, such as Bcl-xL, are upregulated through the NF-kB signaling pathway (Bernal-Mizrachi et al., 2006; Glauert et al., 2008) . Furthermore, the p50 signaling pathway participates in cellular proliferation by regulating interleukin-5 (Yang et al., 1998) , mitogen-associated protein kinase (Yu et al., 2009) , and cyclin D1 (Shukla et al., 2005) .
The human NFKB1 gene encoding p50 is located on chromosome 4q24 and encodes a 50-kDa DNA-binding protein (Sun and Zhang, 2007; Yu et al., 2009 ). The first potential functional NFKB1 polymorphism is rs28362491 (-94 insertion/deletion ATTG), which is located between two putative key promoter regulatory elements. An increasing number of studies have reported an association between rs28362491 and cancer risk, although conflicting results have been obtained (Lewander et al., 2007; Cai et al., 2013; Li et al., 2013) . Moreover, only one study reported that rs28362491 in NFKB1 was significantly associated with ovarian cancer (Huo et al., 2013) . In fact, a limited number of single nucleotide polymorphisms (SNPs) could not effectively capture the true causative SNPs in the NFKB1 gene owing to the weak linkage disequilibrium (LD) between them. Thus, to exactly identify the association of NFKB1 SNPs with ovarian cancer, it is necessary to use a more powerful technique that can identify the SNPs as precisely as possible.
To verify the putative association between the NFKB1 SNPs and ovarian cancer, in the present study we investigated the association between 15 SNPs (rs28362491, rs3774932, rs1598856, rs230531, rs230530, rs230528, rs230521, rs230498, rs230539, rs1005819, rs3774956, rs4648055, rs4648068, rs3774964, rs3774968) of the NFKB1 gene and the risk of ovarian cancer in a Chinese Han population.
MATERIAL AND METHODS

Subjects
All the patients with ovarian cancer underwent careful clinical examinations, including hysteroscopy or hysterosalpingography, transvaginal ultrasound, serial endometrial biopsies, and analyses of tissue antibodies and autoantibodies. Four hundred and ten patients with pathologically confirmed ovarian cancer (mean age of 49.3 ± 8.2 years) were recruited from the in-patient department of gynecology in our hospital from January 2008 to April 2013. Patients with other malignancies were excluded. Four hundred and forty-two women (mean age of 50.6 ± 6.5 years) were recruited as healthy controls in the medical examination center of our hospital. Exclusion criteria were: taking other prescribed medications that could affect the central nervous system; history of seizures, hematological diseases, or severe liver or kidney damage; smoking; hypertension; and previous use of oral contraceptives. All participants were from a non-genetically related Chinese Han population in Zhejiang Province (China). The study was performed according to the guidelines of the Medical Ethics Committee of our hospital (Wenzhou, China). Written informed consent was obtained from all the participants.
SNP selection
A total of 15 SNPs located on the NFKB1 gene with a genomic size of 116 kb were selected for genotyping. Marker selection was done based on previous studies Li et al., 2013) , and preliminary analysis was performed using HapMap data (HapMap data release 27). We examined tagSNPs in the Chinese Han population of Beijing using the Haploview software v4.2, with a minor allele frequency cut-off of ≥5%. The LD pattern of the NFKB1 gene was determined in the Chinese population using the preliminary data from HapMap. The SNPs were further analyzed in an association study.
Genotyping
Peripheral blood (3-5 mL) was collected from the subjects and preserved in tubes coated with ethylenediaminetetraacetic acid. Genomic DNA was extracted using a TIANamp Blood DNA Kit (TIANGEN Biotech, Beijing, China) and stored at -4°C until use. Genotyping was carried out for all SNPs using the MassARRAY platform (Sequenom Inc., San Diego, CA, USA). Primer extension and polymerase chain reaction were performed according to the manufacturer instructions, using iPLEX enzyme (Sequenom Inc.) and HotStarTaq DNA polymerase (Qiagen, Hilden, Germany). The completed genotyping reactions were spotted onto a 384-well SpectroCHIP (Sequenom Inc.) using a MassARRAY Nanodispenser (Sequenom Inc.), and determined by a matrix-assisted laser desorption ionization time-of-flight mass spectrometer. Genotype calling was performed in real-time with the MassARRAY RT software version 3.0.0.4 and analyzed using the MassARRAY Typer software version 3.4 (Sequenom Inc.).
Statistical analysis
All data were analyzed using the SPSS 17.0 software (SPSS Inc., Chicago, IL, USA). Each SNP was tested for deviation from Hardy-Weinberg equilibrium using the Pearson chisquare test or the Fisher exact test. Differences between the cases and controls in the frequency of the alleles and genotypes were evaluated by the Fisher exact test or the Pearson chi-square test. Subject age was treated as a covariate in binary logistic regression. P values were calculated based on codominant, dominant for the rare allele, heterosis, and recessive for the rare allele models of inheritance. Unconditional logistic regression was used to calculate the odds ratio (OR) and 95% confidence interval (CI) in independent association between each locus and the presence of ovarian cancer. Haplotype blocks were defined according to the criteria developed by Gabriel et al. (2002) . Pairwise LD statistics (D' and r 2 ) and haplotype frequency were calculated, and haplotype blocks were constructed using Haploview 4.0 (Barrett et al., 2005) . The significance of any haplotypic association was evaluated using a likelihood ratio test, followed by a permutation testing that compared estimated haplotype frequencies in cases and controls (Zhao et al., 2000 (Zhao et al., , 2002 Curtis et al., 2006 ). Bonferroni's correction was used to adjust the test level when multiple comparisons were conducted, and the P value was divided by the total number of loci.
RESULTS
The genotype frequency and distribution of the 15 SNPs were in agreement with Hardy-Weinberg equilibrium. Pairwise LD analyses of the patients with ovarian cancer and healthy controls revealed that SNPs rs3774932 and rs1598856, SNPs rs230528 and rs230521, SNPs rs3774956 and rs4648055, and SNPs rs4648068, rs3774964, and rs3774968 were located in haplotype blocks 1, 2, 3, and 4, respectively (D' > 0.9; Figure 1 ). The difference in the distribution of genotype frequencies of rs28362491 between the patients with ovarian cancer and healthy controls was significant (P = 0.003). The patients with ovarian cancer had a significantly higher frequency of the ATTG 2 allele (insertion, P = 0.001, OR = 1.367, 95%CI = 1.130-1.653). The analysis revealed an association between the rs230521 genotype distribution and ovarian cancer (P = 0.013). The patients with ovarian cancer had a significantly lower frequency of the G allele (P = 0.003, OR = 0.741, 95%CI = 0.608-0.903). There was a significant between-group difference in the genotype distribution of rs4648068 (P = 0.0005). The patients with ovarian cancer had a significantly lower frequency of the T allele of rs4648068 (P = 0.001, OR = 1.381, 95%CI = 1.141-1.671).
Significantly more A-C (block 2: rs230528-rs230521) haplotypes (P = 0.0003 after Bonferroni's corrections) were found in ovarian cancer subjects. Compared with the healthy controls, significantly more G-A-A (block 4: rs4648068-rs3774964-rs3774968) haplotypes (P = 0.021) were found in the patients with ovarian cancer. However, this association was no longer significantly different after Bonferroni's corrections (P > 0.0167).
DISCUSSION
The activation of NF-kB signaling is frequently found in the pathogenesis of ovarian cancer (Chen et al., 2001; Karin, 2006; Lin et al., 2007; Maeda and Omata, 2008; Annunziata et al., 2010) . Our results provide direct evidence that a genetic change in NFKB1 is linked to ovarian cancer in humans, and extend the list of variants that may affect the development of ovarian cancer (Huo et al., 2013) .
The study of in vitro promoter expression indicated that the ATTG2 allele may increase the mRNA expression of the NFKB1 gene, resulting in the production of p50/p105 NF-kB protein (Karban et al., 2004 those homozygous for ATTG1. Individuals with the ATTG2 allelotype had a 1.493-fold risk of cervical squamous cell carcinoma compared with those carrying the ATTG1 allelotype (Zhou et al., 2010) . A recent study by Fan et al. (2011) suggested that a functional promoter polymorphism in the NFKB1 gene increases the risk of advanced ovarian cancer in a population from Northeast China. In addition, a meta-analysis of all eligible studies in 2010 suggested that the deletion allele serves as a protective or risk allele for cancer susceptibility among Asians or Caucasians, respectively (Zou et al., 2011) . We identified a significant association between a functional polymorphism (rs28362491) in the promoter region of NFKB1 and an increased risk of ovarian cancer. Individuals with the ATTG2 allele (insertion) had a 1.367-fold risk of ovarian cancer compared with non-carriers. Interestingly, the study by Huo et al. (2013) demonstrated that the mRNA level of NFKB1 in EOC tissues significantly correlated with the -94 insertion/deletion ATTG genotype; the highest level of NFKB1 was observed in EOC ATTG2 homozygous tissues. This correlation may be associated with the enhanced expression and activity of p50. It has been reported that the insertion allele is associated with an increased activity of the NFKB1 promoter and enhanced NFKB1 mRNA expression (Karban et al., 2004; Riemann et al., 2007) . Indeed, at least five studies have reported that the presence of the insertion allele is associated with increased cancer risk and aggressive cancer behavior. Lin et al. (2007) have suggested a role for NF-kB in the propaga tion of ovarian cancer cell lines. Moreover, a recent report has revealed that the overactivation of NF-kB may contribute to the development of EOC, and that p50 is significantly associated with the overall poor survival rate of women with EOC (Annunziata et al., 2010) .
In this case-control association study, the G alleles of NFKB1 rs230521 were strongly associated with the decreased risk of ovarian cancer, and the T allele of NFKB1 rs4648068 was associated with decreased risk of ovarian cancer. To the best of our knowledge, this is the first study that reports a significant association of two SNPs (rs230521 and rs4648068) in the NFKB1 gene with ovarian cancer. To some extent, this finding further supports a role of NFKB1 promoter polymorphism in ovarian cancer. Our studies could help reveal the mechanism by which the NFKB1 gene polymorphisms influence the ovarian cancer phenotype. We further investigated the interaction among polymorphisms and observed strong LD. Haplotype analysis revealed that more A-C (rs230528-rs230521) and G-A-A (rs4648068-rs3774964-rs3774968) haplotypes were found in the patients with ovarian cancer, which indicated that these two haplotypes of the NFKB1 gene displayed a risk effect. These results suggest that people with these two haplotypes of the NFKB1 gene are more prone to develop ovarian cancer. This finding further supports a role of NFKB1 polymorphisms in ovarian cancer, with differences in the populations of the association between ethnic groups.
The main strengths of this study include: a systematical screening of the functional SNPs in the promoter region, 5'-and 3'-untranslated region, exons of the NFKB1 gene, and the homogeneity of the study subjects representing the Chinese Han population. The potential limitation of this study is the lack of data proving the positive association observed for rs230521 and rs4648068. Furthermore, the association of the serum level of NFKB1 with ovarian cancer still needs to be investigated.
In conclusion, these findings encourage future efforts aimed at identifying functional polymorphisms within, and close to, the NFKB1 gene using a systemic approach in a larger sample set. Our study could improve the understanding of the mechanism of ovarian cancer, and help in the development of more efficient therapy.
